Hepg2

Cell culture. The human liver cancer cell line HepG2 was purchased from the American Type Culture Collection and maintained in RPMI-1640 (Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% fetal bovine serum (FBS; Zhejiang Tian Hang Biological Science and Technology Co., Ltd.), 2.0 g/l sodium hydrogen carbonate, 100 µg/ml streptomycin and 100 U/ml penicillin. The cells were maintained in an incubator at 37˚C (5% CO 2 ), and experiments were conducted during the exponential growth phase. However, the cell line was not authenticated in our laboratory since it was purchased in 2013.
Cell viability assay. HepG2 cells were cultured in RPMI-1640 supplemented with 10% FBS for 24 h. The cells were then treated with TA (Cell Signaling Technology, Inc.) at 0, 90, 180, 270, 360, 450 and 540 µM, and CDDP (Qilu Pharmaceutical Co., Ltd.) at 0, 0.6, 1.2, 1.8, 2.4, 3.0 and 3.6 µg/ml for 24 h. Subsequently, the cells were subjected to MTT analysis according to the manufacturer's protocol (Solar Biotechnology Co., Ltd.). The cell inhibition rate was calculated as follows:
1-(drug A value-control A value)/inhibition rate (%)=1-(drug A value-control A value)/(control A value-blank A value).